1887
Letter Open Access
Like 0
Preview this article:

There is no abstract available.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.35.2100826
2021-09-02
2021-09-21
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.35.2100826
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/35/eurosurv-26-35-4.html?itemId=/content/10.2807/1560-7917.ES.2021.26.35.2100826&mimeType=html&fmt=ahah

References

  1. Harder T, Koch J, Vygen-Bonnet S, Külper-Schiek W, Pilic A, Reda S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Euro Surveill. 2021;26(28):2100563.  https://doi.org/10.2807/1560-7917.ES.2021.26.28.2100563  PMID: 34269175 
  2. Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351-62.  https://doi.org/10.1016/S0140-6736(21)00628-0  PMID: 33798499 
  3. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-23.  https://doi.org/10.1056/NEJMoa2101765  PMID: 33626250 
  4. Vaccines and Related Biological Products Advisory Committee, U.S.Food and Drug Administration (FDA). mRNA–1273. Sponsor briefing document addendum. Silver Spring: FDA; 17 Dec 2020. Available from: https://www.fda.gov/media/144453/download
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error